The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma...
Takeda announced that a New Drug Application (NDA) has been submitted to the FDA for ixazomib, an investigational oral proteasome...
The oral proteasome inhibitor ixazomib (Ninlaro®) is approved in the USA, EU and Japan in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
The National Institute for Health and Care Excellence (NICE), in a draft recommendation, has rejected Ninlaro (ixazomib) combination with lenalidomide...
Takeda Pharmaceutical Company Limited announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of Ninlaro (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
Takeda and Millennium Oncology have begun a Phase III development programme for ixazomib citrate (MLN 9708), the first oral proteasome...
Takeda Pharmaceutical has announced that the European Commission has granted conditional marketing authorization for Ninlaro (ixazomib) capsules, indicated in combination...
Areas covered: In this review, we provide an overview of the preclinical and early-phase studies of ixazomib used as single-agent and in combination. Furthermore, we discuss the results of a recently published pivotal trial...